SlideShare a Scribd company logo
DRUG STABILITY
INDEX
Introduction
Advantages
Types
Stability evaluation for different formulations
Shelf life estimation
Overage calculation
ICH guidelines
“A measure of how pharmaceutical product
maintains its quality attribute over a time”
Stability
   The USP defines the stability of a
    pharmaceutical product as “ extent to which a
    product retains , with in specified limits, and
    throught out its period of storage and use i.e its
    shelf life, the same properties and
    characteristics that it possesed at the time of its
    manufacture”.
Stability is used to determine
   quality of a drug substance or drug product


   shelf life for the drug product


   Recommended storage conditions
Why stability testing is necessary-
Chemical degradation may lead lowering of


concentrataion of drug in dosage form

toxic product may form due to degradation of
active ingridients
Advantages of stability studies

   Assurance to the pateint


   Economic consideration


   Legal requirements
Types of stability



   Chemical
   Physical
   Microbiological
   Therapeutical
   Toxicological
Stability evaluation for different
           formulations
 1.Tablets
    odour
    colour
    assay
    degradation
    products
    dissolution
    moisture
    hardness/friability.
2. Capsules
   appearance (including
   brittleness),
   colour
   odour of content,
   assay,
   degradation products,
   dissolution,
   moisture and microbial content.
3. Emulsions
   appearance (including phase separation),
   colour,
   odour,
   assay,
   pH, viscosity, microbial limits,
   preservative content, and mean size and
    distribution of dispersed globules.
4. Oral   Solutions and Suspensions


   Additionally for suspensions, redispersibility,
    rheological properties
    mean size and distribution of particles should be
    considered.


5. Oral Powders for Reconstitution


   moisture and reconstitution time.
6.Metered-dose Inhalations and Nasal Aerosols

   appearance (including content, container, valve,
    and its components),
   Dose content uniformity
   labeled number of medication actuations per
    container meeting
   aerodynamic particle size distribution,
   microscopic evaluation,
   water content,
   leak rate,
   microbial limits
7.Topical & Ophthalmic and Preparation
 (ointments, creams, lotions, paste, gel,solutions and non-metered aerosols
forapplication to the skin)




-Topical preparations
   clarity, colour,odour, pH, resuspendability (for
    lotions), consistency,
   viscosity,
    preservative and antioxidant content (if
    present), microbiallimits/sterility and weight
    loss (when appropriate).
-Evaluation of ophthalmic or (e.g., creams, ointments,
solutions,and suspensions)


   Sterility
   particulate matter, and extractable.


-Evaluation of non-metered topical aerosols


   delivery rate,
   microbial limits,
   spray pattern,
   water content, and particle size
8. Suppositories


   softening range, dissolution (at 37 C)
   Microbial limits.


9. Small Volume Parenterals (SVPs) & Large
Volume Parenterals (LVPs)


   particulate matter, pH, sterility and
    pyrogen/endotoxin.
10. Transdermal Patches


   in-vitrorelease rates,
   leakage,
   microbial limits/sterility, peel and adhesive forces, and
   the drug release rate.


11. Freeze-dried Products


   Appearance of both freeze-dried and its reconstituted
    product, assay,
   degradation products, pH, water content and rate of
    solution.
Shelf life estimation
               &
overage calculation
What is shelf life ??

               Shelf life (t0.9)
  It is defined as the time necessary for the drug
   to decay to 90% of its original concentration.
Accelerated analysis for chemical stability

   Based on the principles of chemical kinetics
   Test are carried out at different elevated
    temperature that enables prediction of the
    effective life of the preparation at normal
    temperature
Arrhenius equation
Reaction rates are proportional to the number of
collisions per unit time (of reactant molecules).
The number of collisions increases as the
temperature increases. Therefore, the reaction
rate increases as the temperature increases
according to Arrhenius equation.
K = reaction rate constant
A = frequency factor constant i.e maximum
number of collisions at infinite temperature
Ea = Energy of activation
T = absolute temperature (Kelvin)
Arrhenius plot:
   Click to edit Master text styles
    
        Second level
    
        Third level
         
             Fourth level
               
                 Fifth level
1.According to the Garrett and carper “the
k value for decompostion of a drug in
solution at various elevated temperature are
obtained by plotting some function of
concentration against time”.
Accelerated breakdown of a drug in solution at various
              elevated temperature
2. The log of specific rates of
decomposition are than plotted aginst the
reciprocal of the absolute temperature and
the resulting line are extraplotted to room
temperature
Predicting drug stability at room temperature by Arrhenius
plot
3. Free and Blythe suggested a similar
method in which the fractional life period is
plotted against reciprocal temperature, and
the time in days required for the drug to
decompose to some fraction of its original
potency at R.T is obtained.
Log plot of t90 against reciprocal temperature
4. The log % of the drug remaining is
plotted against time in days and the time
for the potency to fall to 90% of the
original value i.e t90 is read from the graph.
The log time to 90% is then plotted against
1/T and the time at 25 degree c gives the
shelf life of the product in days
Time in days required for drug ptency at fall 90% t90 are than plotted on a log
scale
Limitations of accelerated analysis
   Carried out only at final package container
   Prediction is not possible at all climatic
    conditions
   Limited to the product formulations
   Only apply to the those which degrade with
    increase in temperature
Long term stability studies

   Click to edit Master text styles
       Second level
       Third level
            Fourth level
               
                 Fifth level
2 side 95%
confidence
limit
Overage


It is over loading the dosage form with more
drug than 100% (i.e 110% or more) to give more time to get 90%
    potency i.e. shelf life is longer.

Rational
   Shelf lives are usually a maximum of 5 years and it takes a
    product up to 2 years to reach customer
   Reduced shelf lives are seen in liquid products e.g,
    antibiotics and ophthalmics because they are unstable in
    presence of moisture
   Some drugs are inherently unstable e.g, vitamins. Therefore,
    they are over loaded.
   Click to edit Master text styles
       Second level
       Third level
         
             Fourth level
               
                 Fifth level
ICH guidelines…………………

   ICH stands for International Conference on
    Harmonization of Technical Requirements for
    Registration of Pharmaceuticals for Human
    use.

Objective
     Harmonization of registration application
    within the three regions of the EU, Japan and
    the United States.
   ensure and assess the safety, quality and
    efficacy of medicines.


The zone concept-

      The whole world is divided into 4 climatic
    zones in order to harmonize and simplify
    stablity testing:
Stability testing
Stability Studies are preformed on

Drug Substances                      Drug Products



                   Stress Testing
                 Selection of Batches
            Container Closure System
                   Specification
             Testing Frequency
                  Storage Conditions
             Stability Commitment
                     Evaluation
                 Statements/Labeling
Drug substance General case

                                           Minimum time period
                   Storage condition       covered by data at
   Study                                   submission
Long term          25°C ± 2°C / 60% ± 5%   12 months
                   r.h or
                   30°C ± 2°C / 65% ± 5%
                   r.h.

Intermediate       30°C ± 2°C / 65% ± 5%   6 months
                   r.h.
Accelerated        40°C ± 2°C / 75% ± 5%   6 months
                   r.h.
Drug substances intended for storage in a freezer




Study                 Storage condition      Minimum time period
                                             covered by data at
                                             submission

Long term             -20°C ± 5°C            12 months
Drug substances intended for storage in a refrigerator


Study                   Storage condition       Minimum time period
                                                covered by data at
                                                submission

Long term               5°C ± 3°C               12 months

Accelerated             25°C ± 2°C / 60% ± 5%   6 months
                        r.h.
Drug product general case

Study                Storage condition       Minimum time period
                                             covered by data at
                                             submission
Long term            25°C ± 2°C / 40% ± 5%   12 months
                     r.h. or
                     30°C ± 2°C / 35% ± 5%
                     r.h.

Intermediate         30°C ± 2°C / 65% ± 5%   6 months
                     r.h.
Accelerated          30°C ± 2°C / 65% ± 5%   6 months
                     r.h.
Storage in refrigerator
Study             Storage condition       Minimum time period
                                          covered by data at
                                          submission
Long term         5°C ± 3°C               12 months

Accelerated       25°C ± 2°C / 60% ± 5%   6 months
                  r.h.
THANK
 YOU

More Related Content

PPT
Stability Testing for Drug Substances and Drug Products
PPTX
Ich guidelines for stability studies 2
PPTX
Presentation on-stability-study of pharmaceutical product
PPT
Stability testing and shelf life estimation
PPTX
WHO Guideline & Stability Protocols for Liquid Dosage Forms
PPTX
ICH-Stability of finished products
PPTX
Over View Of Stability Studies
PPTX
Stability and stability testing
Stability Testing for Drug Substances and Drug Products
Ich guidelines for stability studies 2
Presentation on-stability-study of pharmaceutical product
Stability testing and shelf life estimation
WHO Guideline & Stability Protocols for Liquid Dosage Forms
ICH-Stability of finished products
Over View Of Stability Studies
Stability and stability testing

What's hot (20)

PPTX
STABILITY TESTING DURING PRODUCT DEVELOPMENT
PDF
DATION OF EQUIPMENT ICH AND WHO GUIDELINES FOR CALIBRATION AND VALIDATION OF ...
PPTX
Pharmaceuticals Dispersion theory- Suspension and Emulsion
PPTX
Stability testing ppt.pptx
PPTX
Drug excipient interaction different method
PPTX
Quality by design in pharmaceutical development
PPTX
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
PDF
Non clinical drug development. ppt
PPTX
Scale up and post approval changes(supac)
PPTX
Stability studies
PPTX
stability tests for pharmaceutical products
PPT
Evaluation of transdermal drug delivery system
PPTX
Product Stability Studies & Stability Testing
PPTX
validation of dosage forms
PPTX
PPTX
Dissolution profile comparison
PPTX
Optimization techniques in pharmaceutical formulation and processing
PPTX
sustained release drug delivery system
PPTX
ANDA regulatory approval process
PPT
Solid state stability and shelf-life assignment, Stability protocols,reports ...
STABILITY TESTING DURING PRODUCT DEVELOPMENT
DATION OF EQUIPMENT ICH AND WHO GUIDELINES FOR CALIBRATION AND VALIDATION OF ...
Pharmaceuticals Dispersion theory- Suspension and Emulsion
Stability testing ppt.pptx
Drug excipient interaction different method
Quality by design in pharmaceutical development
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
Non clinical drug development. ppt
Scale up and post approval changes(supac)
Stability studies
stability tests for pharmaceutical products
Evaluation of transdermal drug delivery system
Product Stability Studies & Stability Testing
validation of dosage forms
Dissolution profile comparison
Optimization techniques in pharmaceutical formulation and processing
sustained release drug delivery system
ANDA regulatory approval process
Solid state stability and shelf-life assignment, Stability protocols,reports ...
Ad

Viewers also liked (11)

PDF
Q1 d step4
PDF
ICH Q1D (Bracketing and Matrixing Designs for Stability Testing of New Drug S...
PPTX
Stability testing
PPSX
effect of various environment and processing on stability of formulations
PPT
Dissolution Testing in Pharmaceuticals
PPT
PPT
Tablet friability,harness and dissolution testing
PPTX
NOVEL DRUG DELIVERY SYSTEM REVIEW
PPT
Tablets
PPTX
Stability studies of drugs
PPT
Bacterial Endotoxin Test
Q1 d step4
ICH Q1D (Bracketing and Matrixing Designs for Stability Testing of New Drug S...
Stability testing
effect of various environment and processing on stability of formulations
Dissolution Testing in Pharmaceuticals
Tablet friability,harness and dissolution testing
NOVEL DRUG DELIVERY SYSTEM REVIEW
Tablets
Stability studies of drugs
Bacterial Endotoxin Test
Ad

Similar to Stability testing (20)

PPTX
Dry powder, Meter dose and Nebulizer inhaler
PPTX
Stability testing protocols for Pharmacy students.pptx
PDF
ICH Stability Testing Guidelines ONline 9-5-24.pdf
PDF
ICH Stability Testing Guidelines ONline 9-5-24.pdf
PPTX
1. Drug stability for Pharmacy students, ppt
PDF
Stability studies
PPTX
Power point presentation shweta patil.
PPTX
Power point presentation shweta patil.
PDF
Accelerated stability studies
PPTX
ICH STABILITY TESTING GUIDELINES (ICH Q1A-Q1F).pptx
PPTX
ICH STABILITY TESTING GUIDELINES:
PPTX
Stability basic concepts and purposes
PPTX
Stability study
PDF
Accelerated stability studies / B.Pharm II Yr / IV Semester
PDF
Stability pharma
PPTX
Accelerated Stability Studies.pptx
PDF
ICH guidelines for stability studies
PPTX
Stability Presentation.pptx
PPT
Presentation 1
PDF
Stability studies
Dry powder, Meter dose and Nebulizer inhaler
Stability testing protocols for Pharmacy students.pptx
ICH Stability Testing Guidelines ONline 9-5-24.pdf
ICH Stability Testing Guidelines ONline 9-5-24.pdf
1. Drug stability for Pharmacy students, ppt
Stability studies
Power point presentation shweta patil.
Power point presentation shweta patil.
Accelerated stability studies
ICH STABILITY TESTING GUIDELINES (ICH Q1A-Q1F).pptx
ICH STABILITY TESTING GUIDELINES:
Stability basic concepts and purposes
Stability study
Accelerated stability studies / B.Pharm II Yr / IV Semester
Stability pharma
Accelerated Stability Studies.pptx
ICH guidelines for stability studies
Stability Presentation.pptx
Presentation 1
Stability studies

More from Gaurav Kr (20)

PPT
Instrumental analysis
PPT
Investigational new drug application
PPT
Fractional factorial design tutorial
PPT
Herbals
PPT
Herbal medicine
PPT
Investigational new drug application
PPT
Gmp for water for p'cal use
PPT
Gmp compliance
PPT
GMP and cGMP
PPT
Foi and iig
PPT
Drug master files
PPT
Drug development and nda
PPT
EMEA
PPT
Dosage form design
PPT
Control of microbial growth
PPT
Computer system validation
PPT
Designing around patent
PPT
Clinical trails
PPT
Clinical study and gcp
PPT
Clinical research
Instrumental analysis
Investigational new drug application
Fractional factorial design tutorial
Herbals
Herbal medicine
Investigational new drug application
Gmp for water for p'cal use
Gmp compliance
GMP and cGMP
Foi and iig
Drug master files
Drug development and nda
EMEA
Dosage form design
Control of microbial growth
Computer system validation
Designing around patent
Clinical trails
Clinical study and gcp
Clinical research

Stability testing

  • 2. INDEX Introduction Advantages Types Stability evaluation for different formulations Shelf life estimation Overage calculation ICH guidelines
  • 3. “A measure of how pharmaceutical product maintains its quality attribute over a time”
  • 4. Stability  The USP defines the stability of a pharmaceutical product as “ extent to which a product retains , with in specified limits, and throught out its period of storage and use i.e its shelf life, the same properties and characteristics that it possesed at the time of its manufacture”.
  • 5. Stability is used to determine  quality of a drug substance or drug product  shelf life for the drug product  Recommended storage conditions
  • 6. Why stability testing is necessary- Chemical degradation may lead lowering of  concentrataion of drug in dosage form toxic product may form due to degradation of active ingridients
  • 7. Advantages of stability studies  Assurance to the pateint  Economic consideration  Legal requirements
  • 8. Types of stability  Chemical  Physical  Microbiological  Therapeutical  Toxicological
  • 9. Stability evaluation for different formulations 1.Tablets  odour  colour  assay  degradation  products  dissolution  moisture  hardness/friability.
  • 10. 2. Capsules  appearance (including  brittleness),  colour  odour of content,  assay,  degradation products,  dissolution,  moisture and microbial content.
  • 11. 3. Emulsions  appearance (including phase separation),  colour,  odour,  assay,  pH, viscosity, microbial limits,  preservative content, and mean size and distribution of dispersed globules.
  • 12. 4. Oral Solutions and Suspensions  Additionally for suspensions, redispersibility, rheological properties  mean size and distribution of particles should be considered. 5. Oral Powders for Reconstitution  moisture and reconstitution time.
  • 13. 6.Metered-dose Inhalations and Nasal Aerosols  appearance (including content, container, valve, and its components),  Dose content uniformity  labeled number of medication actuations per container meeting  aerodynamic particle size distribution,  microscopic evaluation,  water content,  leak rate,  microbial limits
  • 14. 7.Topical & Ophthalmic and Preparation (ointments, creams, lotions, paste, gel,solutions and non-metered aerosols forapplication to the skin) -Topical preparations  clarity, colour,odour, pH, resuspendability (for lotions), consistency,  viscosity,  preservative and antioxidant content (if present), microbiallimits/sterility and weight loss (when appropriate).
  • 15. -Evaluation of ophthalmic or (e.g., creams, ointments, solutions,and suspensions)  Sterility  particulate matter, and extractable. -Evaluation of non-metered topical aerosols  delivery rate,  microbial limits,  spray pattern,  water content, and particle size
  • 16. 8. Suppositories  softening range, dissolution (at 37 C)  Microbial limits. 9. Small Volume Parenterals (SVPs) & Large Volume Parenterals (LVPs)  particulate matter, pH, sterility and pyrogen/endotoxin.
  • 17. 10. Transdermal Patches  in-vitrorelease rates,  leakage,  microbial limits/sterility, peel and adhesive forces, and  the drug release rate. 11. Freeze-dried Products  Appearance of both freeze-dried and its reconstituted product, assay,  degradation products, pH, water content and rate of solution.
  • 18. Shelf life estimation & overage calculation
  • 19. What is shelf life ?? Shelf life (t0.9) It is defined as the time necessary for the drug to decay to 90% of its original concentration.
  • 20. Accelerated analysis for chemical stability  Based on the principles of chemical kinetics  Test are carried out at different elevated temperature that enables prediction of the effective life of the preparation at normal temperature
  • 21. Arrhenius equation Reaction rates are proportional to the number of collisions per unit time (of reactant molecules). The number of collisions increases as the temperature increases. Therefore, the reaction rate increases as the temperature increases according to Arrhenius equation.
  • 22. K = reaction rate constant A = frequency factor constant i.e maximum number of collisions at infinite temperature Ea = Energy of activation T = absolute temperature (Kelvin)
  • 23. Arrhenius plot:  Click to edit Master text styles  Second level  Third level  Fourth level  Fifth level
  • 24. 1.According to the Garrett and carper “the k value for decompostion of a drug in solution at various elevated temperature are obtained by plotting some function of concentration against time”.
  • 25. Accelerated breakdown of a drug in solution at various elevated temperature
  • 26. 2. The log of specific rates of decomposition are than plotted aginst the reciprocal of the absolute temperature and the resulting line are extraplotted to room temperature
  • 27. Predicting drug stability at room temperature by Arrhenius plot
  • 28. 3. Free and Blythe suggested a similar method in which the fractional life period is plotted against reciprocal temperature, and the time in days required for the drug to decompose to some fraction of its original potency at R.T is obtained.
  • 29. Log plot of t90 against reciprocal temperature
  • 30. 4. The log % of the drug remaining is plotted against time in days and the time for the potency to fall to 90% of the original value i.e t90 is read from the graph. The log time to 90% is then plotted against 1/T and the time at 25 degree c gives the shelf life of the product in days
  • 31. Time in days required for drug ptency at fall 90% t90 are than plotted on a log scale
  • 32. Limitations of accelerated analysis  Carried out only at final package container  Prediction is not possible at all climatic conditions  Limited to the product formulations  Only apply to the those which degrade with increase in temperature
  • 33. Long term stability studies  Click to edit Master text styles  Second level  Third level  Fourth level  Fifth level
  • 35. Overage It is over loading the dosage form with more drug than 100% (i.e 110% or more) to give more time to get 90% potency i.e. shelf life is longer. Rational  Shelf lives are usually a maximum of 5 years and it takes a product up to 2 years to reach customer  Reduced shelf lives are seen in liquid products e.g, antibiotics and ophthalmics because they are unstable in presence of moisture  Some drugs are inherently unstable e.g, vitamins. Therefore, they are over loaded.
  • 36. Click to edit Master text styles  Second level  Third level  Fourth level  Fifth level
  • 37. ICH guidelines…………………  ICH stands for International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use. Objective  Harmonization of registration application within the three regions of the EU, Japan and the United States.
  • 38. ensure and assess the safety, quality and efficacy of medicines. The zone concept- The whole world is divided into 4 climatic zones in order to harmonize and simplify stablity testing:
  • 40. Stability Studies are preformed on Drug Substances Drug Products  Stress Testing  Selection of Batches  Container Closure System  Specification  Testing Frequency  Storage Conditions  Stability Commitment  Evaluation  Statements/Labeling
  • 41. Drug substance General case Minimum time period Storage condition covered by data at Study submission Long term 25°C ± 2°C / 60% ± 5% 12 months r.h or 30°C ± 2°C / 65% ± 5% r.h. Intermediate 30°C ± 2°C / 65% ± 5% 6 months r.h. Accelerated 40°C ± 2°C / 75% ± 5% 6 months r.h.
  • 42. Drug substances intended for storage in a freezer Study Storage condition Minimum time period covered by data at submission Long term -20°C ± 5°C 12 months
  • 43. Drug substances intended for storage in a refrigerator Study Storage condition Minimum time period covered by data at submission Long term 5°C ± 3°C 12 months Accelerated 25°C ± 2°C / 60% ± 5% 6 months r.h.
  • 44. Drug product general case Study Storage condition Minimum time period covered by data at submission Long term 25°C ± 2°C / 40% ± 5% 12 months r.h. or 30°C ± 2°C / 35% ± 5% r.h. Intermediate 30°C ± 2°C / 65% ± 5% 6 months r.h. Accelerated 30°C ± 2°C / 65% ± 5% 6 months r.h.
  • 45. Storage in refrigerator Study Storage condition Minimum time period covered by data at submission Long term 5°C ± 3°C 12 months Accelerated 25°C ± 2°C / 60% ± 5% 6 months r.h.